title: Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
abstract: OBJECTIVE
  To assess the efficacy of a combination of oral and topical 5-aminosalicylic acid (5-ASA) for the maintenance treatment of ulcerative colitis, we undertook a double-blind randomized clinical trial.
  
  
  METHODS
  Patients aged 18 to 65 yr (with disease extent greater than proctitis only) were eligible for inclusion in the study if they met the following criteria: (a) history of two or more relapses in the last year; (b) achievement of remission in the last 3 months (with maintenance of remission for at least 1 month). Patients enrolled in the study were randomly assigned to one of the two following 1-yr treatments: (1) combined therapy with 5-ASA tablets 1.6 g/day and 5-ASA enemas 4 g/100 ml twice weekly; (2) oral therapy with 5-ASA tablets 1.6 g/day and placebo enemas/twice weekly. The main end point of the study was the maintenance of remission at 12 months.
  
  
  RESULTS
  Upon completion of the study, relapse occurred in 13 of 33 patients in the combined treatment group versus 23 of 36 patients in the oral treatment group (39 vs 69%; p = 0.036). No significant side effects related to treatment were observed in either group. A simplified pharmacoeconomic analysis shows that this form of combined treatment can have a favorable cost-effectiveness ratio.
  
  
  CONCLUSIONS
  Our results indicate that 5-ASA given daily by oral route and intermittently by topical route can be more effective than oral therapy alone. This form of combination treatment can be appropriate for patients at high risk of relapse.
authors.affiliation: Gastroenterologia Ospedale Civile Grosseto, Istituto di Anatomia Patologica, Università di Firenze, Italy.
authors.forename: G
authors.initials: G
authors.lastname: d'Albasio
authors.forename: F
authors.initials: F
authors.lastname: Pacini
authors.forename: E
authors.initials: E
authors.lastname: Camarri
authors.forename: A
authors.initials: A
authors.lastname: Messori
authors.forename: G
authors.initials: G
authors.lastname: Trallori
authors.forename: A G
authors.initials: AG
authors.lastname: Bonanomi
authors.forename: G
authors.initials: G
authors.lastname: Bardazzi
authors.forename: M
authors.initials: M
authors.lastname: Milla
authors.forename: S
authors.initials: S
authors.lastname: Ferrero
authors.forename: M
authors.initials: M
authors.lastname: Biagini
authors.forename: S
authors.initials: S
authors.lastname: Quaranta
authors.forename: A
authors.initials: A
authors.lastname: Amorosi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004733:Enema; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine; D008875:Middle Aged; D012008:Recurrence
chemical_list: D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine